Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner
<p>Inhibition of hNa<sub>v</sub>1.5 channels by aripiprazole: Representative current traces obtained for control (Co) and in the presence of 3 µM aripiprazole (ari: 3). Channel activations were carried out by short depolarizations to −20 mV for 5 ms from a holding potential of −85 mV.</p> "> Figure 2
<p>Interaction with the resting state. Relative current amplitudes versus the concentration of aripiprazole are illustrated. Channel activations in the absence (control) and presence of different concentrations of aripiprazole (test) were carried out from a holding potential of −140 mV (insert). Current amplitudes obtained for the test pulses were related to their controls and plotted against the concentration of aripiprazole. Data points were fit to Equation (1). Note, even at the highest concentration of aripiprazole (10 µM), the inhibitory effect small. Thus, the calculated affinity (K<sub>r</sub>: 54.7 ± 13.0 µM) has to be considered as an approximate estimation.</p> "> Figure 3
<p>(<b>A</b>) Voltage dependence of activation. The graph illustrates representative data obtained from one typical cell. Normalized peak conductances in the absence (control 1 and 2; open circles and triangles) and presence of 1 µM aripiprazole (filled circles) versus test pulse potential are shown. The potential difference in activation midpoints between control 1 and 2 was taken into account as the drug-independent shift. Altogether, mean half-maximal activation for control 1 and 2 occurred at –43.6 ± 3.0 mV and −45.2 ± 3.4 mV with a mean slope of 6.5 mV. The corresponding values in the presence of 1 µM aripiprazole were −46.5 ± 4.2 mV, slope 6.7 mV. Insert: Experimental scheme. Starting from a holding potential of −140 mV, test pulses for 5 ms to potentials ranging from −90 to +20 mV (increment 5 mV) were carried out. Interpulse interval was 5 s. (<b>B</b>) Overlay of original current traces (control 1) obtained for the data shown in (<b>C</b>) Peak current amplitudes at different test pulse potentials from the traces shown in (<b>B</b>). All data are from the same cell.</p> "> Figure 4
<p>Voltage dependence of fast inactivation. (<b>A</b>) Data of normalized peak currents are plotted against the prepulse potential. Solid lines represent fits according to Equation (4). Insert: Experimental scheme. Voltage dependence of fast-inactivation was determined by measuring sodium currents elicited by 5 ms depolarizations to −20 mV after conditioning prepulses for 500 ms to different potentials (range −140 to −50 mV) in the absence (open circles) and presence (filled circles) of 1 µM aripiprazole. Holding potential was −140 mV. (<b>B</b>) Overlay of original current traces obtained for control. (<b>C</b>) Relative shift of inactivation midpoints in relation to the applied concentration of aripiprazole. Data are corrected for the drug-independent shift (1.0 mV/measuring cycle) and fitted according to Equation (6) using the mean slope obtained in the presence of aripiprazole. The fit gives an affinity of 0.5 ± 0.14 µM for the fast-inactivated state.</p> "> Figure 5
<p>Voltage dependence of slow inactivation. (<b>A</b>) Data of normalized peak currents from a representative cell are plotted versus the prepulse potential. Solid lines are fits according to Equation (5) for control (open circles) and different concentrations of aripiprazole (filled symbols). The experimental scheme as illustrated by the insert of B consisted of channel activations to −20 mV after long-lasting (10 s) conditioning prepulses to different potentials and a short (20 ms) recovery period at −140 mV immediately before the test pulse. (<b>B</b>) Normalized data for 1 µM aripiprazole were obtained by dividing the values obtained in the presence of 1 µM aripiprazole by those obtained for control. It is evident that current amplitudes continuously decreased with an increase in prepulse potential. (<b>C</b>) Concentration response curve taken from normalized current amplitudes obtained at the prepulse potential of 0 mV. The affinity to the slow inactivated state (K<sub>i</sub>) obtained from this experiment is given in the insert and was obtained from a fitting of data according to Equation (1). Altogether, an affinity for the slow inactivated state of 0.39 ± 0.07 µM resulted.</p> "> Figure 6
<p>Time course of block development. (<b>A</b>) The graph illustrates relative current amplitudes in dependence on the duration of the inactivating prepulse for control (open circles) and in the presence of different concentrations of aripiprazole (filled symbols). Solid lines represent fits of single (control) or double exponential functions (in the presence of aripiprazole). (<b>B</b>) Experimental scheme for an individual sweep. Channels were inactivated at −20 mV for a variable duration. Immediately before the test pulse a short recovery period was inserted. The amplitude of the inactivating current was used as control. Interval between individual sweeps was 5 s. (<b>C</b>,<b>D</b>). The inverse of the time constants of the data shown in A were plotted versus the concentration of aripiprazole. Association (k<sub>on</sub>) and dissociation rate constants (k<sub>off</sub>) were estimated from the slope and y-intercept of the linear fit. Inserts give fit data for this particular experiment. Altogether affinity constants for the fast and slow time constants were 0.55 µM and 0.38 µM, respectively. This evaluation was performed under the reservation that the data from the individual terms were allowed to be handled separately, as mentioned in the discussion.</p> "> Figure 7
<p>Apparent affinity. (<b>A</b>) The graph illustrates relative current amplitudes in the presence of different concentrations of aripiprazole (black circles represent measured normalized current amplitudes, solid line is the result of the fit to Equation (1)). (<b>B</b>) Original current traces obtained from channel activations carried out according to the protocol illustrated in <a href="#ijms-23-12890-f001" class="html-fig">Figure 1</a>. The holding potential was set close to half-maximal inactivation (here: −90 mV). Aripiprazole was preincubated for 10 s before the test pulse was given. Interval between individual sweeps was 10 s. The apparent affinity (K<sub>app</sub>) was obtained from a fit of data according to Equation (1). For calculating the affinity to the inactivated state (K<sub>i</sub>), Equation (7) was employed, which respects the affinity to the resting state (K<sub>r</sub>) and the amount (h) of currently available (not-inactivated) channels. Fit parameters for this cell are shown as insert. Altogether, a K<sub>i</sub> of 2.14 ± 1.16 µM was estimated.</p> "> Figure 8
<p>Recovery from inactivation. (<b>A</b>) Overlay of 19 original current traces obtained for control from the initial part of the conditioning inactivation pulses (inact.), which served as control and their corresponding test pulses (test). The variable recovery time is not illustrated. (<b>B</b>) Recovery from fast inactivation was performed using an inactivation time of 500 ms. The relative amount of available channels expressed as relative current amplitude (test/inact.) versus the recovery time at −140 mV is illustrated. The pulse protocol is illustrated by the inset. Interval between individual sweeps was 10 s and aripiprazole was applied at 1 µM. Solid lines represent fits with two exponential functions according to Equation (11). (<b>C</b>) Otherwise identical protocol as in (<b>B</b>), but with the inactivation time set to 5 s.</p> "> Figure 9
<p>Analysis for use-dependence. Short activations (1 ms) were carried out at a frequency of 10 Hz in the absence and presence of 10 µM aripiprazole. Current amplitudes declined under control from the first to the last activation (50th pulse) by 1.8 ± 1.1%. In the presence of aripiprazole (10 µM), current reduction amounted to 8.2 ± 2.1%. Aripiprazole was preincubated for 20 s.</p> "> Figure 10
<p>Interaction with the open state. (<b>A</b>) Original current traces obtained from the inactivation deficient mutant Nav1.5_CW in the absence and presence of different concentrations of aripiprazole. Individual activations were carried out from a holding potential of −140 mV by stepping to −20 mV for 50 ms. Drugs were preincubated for 60 s before individual activations were carried out. (<b>B</b>) For evaluation, relative plateau current amplitudes (measured at the end of the depolarization) were plotted versus the concentration of aripiprazole (the amplitude obtained for control was set to 1). Data fitting according to Equation (1) revealed fit parameters of this experiment as illustrated. K<sub>o</sub> indicates the affinity for the open state. Altogether, an affinity for the open state of 0.94 ± 0.25 µM was estimated.</p> "> Figure 11
<p>Time course of block development at the F1760K mutant. (<b>A</b>) Identical experiments as shown by <a href="#ijms-23-12890-f006" class="html-fig">Figure 6</a> were carried out with the F1760K mutant. Note: differently to the wildtype, time course of block development for the mutant can be described with one single exponential function. (<b>B</b>) Inverse of the time constants versus the concentration of aripiprazole. Listed fit parameters refer to this particular experiment. Altogether, a K<sub>i</sub> of 2.39 ± 0.28 was estimated.</p> ">
Abstract
:1. Introduction
2. Results
2.1. Aripiprazole Blocks hNav1.5 Channels
2.2. Interaction with the Resting State
2.3. Voltage Dependence of Activation
2.4. Voltage Dependence of Fast Inactivation
2.5. Interaction with the Slow Inactivated State
2.6. Block Development: Kinetic Parameters
2.7. Estimation of Apparent Affinities: Steady-State Parameters
2.8. Recovery from Inactivation
2.9. Interaction with the Open State
2.10. Binding Site
3. Discussion
3.1. Side Effects—Pharmacological Safety
3.2. Other Clinical Implications
4. Methods
4.1. Cell Culture
4.2. Electrophysiology
4.3. Drug Application
4.4. Chemicals
4.5. Data Analysis and Statistics
- (A)
- Concentration-inhibition curves for the estimation of half-maximal effective concentrations (IC50) were fit to the Hill equation:
- (B)
- Voltage dependence of activation
- (C)
- Voltage dependence of inactivation
- (D)
- Interaction with the inactivated state
- (1)
- Shift of inactivation curves/midpoints
- (2)
- Estimation of apparent binding constants
- (3)
- Time- and concentration-dependent development of block
- (E)
- Recovery from inactivation
4.6. Statistics
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Catterall, W.A.; Goldin, A.L.; Waxman, S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57, 397–409. [Google Scholar] [CrossRef] [PubMed]
- Patino, G.A.; Isom, L.L. Electrophysiology and beyond: Multiple roles of Na+ channel β subunits in development and disease. Neurosci. Lett. 2010, 486, 53–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Theile, J.W.; Cummins, T.R. Recent Developments Regarding Voltage-Gated Sodium Channel Blockers for the Treatment of Inherited and Acquired Neuropathic Pain Syndromes. Front. Pharmacol. 2011, 2, 54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumar, A.; Singh, H.; Mishra, A.; Mishra, A.K. Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review. Curr. Drug Discov. Technol. 2020, 17, 23–29. [Google Scholar] [CrossRef] [PubMed]
- Deb, S.; Farmah, B.K.; Arshad, E.; Deb, T.; Roy, M.; Unwin, G.L. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder—A systematic review. Res. Dev. Disabil. 2014, 35, 711–725. [Google Scholar] [CrossRef]
- Kaneriya, S.H.; Robbins-Welty, G.A.; Smagula, S.F.; Karp, J.F.; Butters, M.A.; Lenze, E.J.; Mulsant, B.H.; Blumberger, D.; Anderson, S.J.; Dew, M.A.; et al. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial. JAMA Psychiatry 2016, 73, 329–336. [Google Scholar] [CrossRef] [Green Version]
- Britnell, S.R.; Jackson, A.D.; Brown, J.N.; Capehart, B.P. Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review. Clin. Neuropharmacol. 2017, 40, 273–278. [Google Scholar] [CrossRef]
- Wang, S.; Wei, Y.-Z.; Yang, J.-H.; Zhou, Y.-M.; Cheng, Y.-H.; Yang, C.; Zheng, Y. The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis. Psychiatry Res. 2017, 254, 24–32. [Google Scholar] [CrossRef]
- Casey, A.B.; Canal, C.E. Classics in Chemical Neuroscience: Aripiprazole. ACS Chem. Neurosci. 2017, 8, 1135–1146. [Google Scholar] [CrossRef] [Green Version]
- Ford, C.P. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 2014, 282, 13–22. [Google Scholar] [CrossRef]
- Tuplin, E.W.; Holahan, M.R. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr. Neuropharmacol. 2017, 15, 1192–1207. [Google Scholar] [CrossRef] [Green Version]
- Keck, P.E.; McElroy, S.L. Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic. Expert Opin. Investig. Drugs 2003, 12, 655–662. [Google Scholar] [CrossRef]
- Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.-X.; Sibley, D.R.; Roth, B.L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28, 1400–1411. [Google Scholar] [CrossRef] [Green Version]
- Meng, M.; Li, W.; Zhang, S.; Wang, H.; Sheng, J.; Wang, J.; Li, C. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: Meta-analysis of currently available randomized controlled trials. Shanghai Arch. Psychiatry 2015, 27, 4–17. [Google Scholar] [CrossRef]
- Jen, Y.-W.; Hwang, T.-J.; Chan, H.-Y.; Hsieh, M.H.; Liu, C.-C.; Liu, C.-M.; Hwu, H.-G.; Kuo, C.-H.; Lin, Y.-T.; Chien, Y.-L.; et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: A biomarker for rebound in psychotic symptoms? BMC Psychiatry 2020, 20, 552. [Google Scholar] [CrossRef]
- Koprivica, V.; Regardie, K.; Wolff, C.; Fernalld, R.; Murphy, J.J.; Kambayashi, J.; Kikuchi, T.; Jordan, S. Aripiprazole protects cortical neurons from glutamate toxicity. Eur. J. Pharmacol. 2011, 651, 73–76. [Google Scholar] [CrossRef]
- Gil, C.H.; Kim, Y.R.; Lee, H.J.; Jung, D.H.; Shin, H.K.; Choi, B.T. Aripiprazole exerts a neuroprotective effect in mouse focal cerebral ischemia. Exp. Ther. Med. 2018, 15, 745–750. [Google Scholar] [CrossRef] [Green Version]
- Chen, A.T.; Nasrallah, H.A. Neuroprotective effects of the second generation antipsychotics. Schizophr. Res. 2019, 208, 1–7. [Google Scholar] [CrossRef]
- Zhuo, C.; Xun, Z.; Hou, W.; Ji, F.; Lin, X.; Tian, H.; Zheng, W.; Chen, M.; Liu, C.; Wang, W.; et al. Surprising Anticancer Activities of Psychiatric Medications: Old Drugs Offer New Hope for Patients With Brain Cancer. Front. Pharmacol. 2019, 10, 1262. [Google Scholar] [CrossRef]
- Polcwiartek, C.; Sneider, B.; Graff, C.; Taylor, D.; Meyer, J.; Kanters, J.K.; Nielsen, J. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: A systematic review with a meta-analytic approach. Psychopharmacology 2015, 232, 3297–3308. [Google Scholar] [CrossRef]
- Russo, L.; Di Vincenzo, A.; Rizzo, A.; Rossato, M.; Vettor, R. Aripiprazole Overdose and Transient 2:1 Second Degree Atrioventricular Block: Only A Coincidence? CDS 2019, 14, 155–157. [Google Scholar] [CrossRef] [PubMed]
- Friedrich, M.-E.; Winkler, D.; Konstantinidis, A.; Huf, W.; Engel, R.; Toto, S.; Grohmann, R.; Kasper, S. Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013. Int. J. Neuropsychopharmacol. 2020, 23, 67–75. [Google Scholar] [CrossRef] [Green Version]
- Cavanna, A.; Seri, S.; Cox, J. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. PHMT 2016, 7, 57–64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, J.; Cho, K.-H.; Lee, H.J.; Choi, J.-S.; Rhie, D.-J. Open channel block of Kv1.4 potassium channels by aripiprazole. Korean J. Physiol. Pharmacol. 2020, 24, 545–553. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.; Lee, H.-A.; Choi, S.W.; Kim, S.J.; Kim, K.-S. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Appl. Pharmacol. 2016, 296, 42–53. [Google Scholar] [CrossRef]
- Lee, S.; Lee, H.-A.; Kim, S.; Kim, K.-S. Cellular mechanisms for trazodone-induced cardiotoxicity. Hum. Exp. Toxicol. 2016, 35, 501–510. [Google Scholar] [CrossRef]
- Brauner, J.M.; Hessler, S.; Groemer, T.W.; Alzheimer, C.; Huth, T. Risperidone inhibits voltage-gated sodium channels. Eur. J. Pharmacol. 2014, 728, 100–106. [Google Scholar] [CrossRef]
- An, J.R.; Seo, M.S.; Jung, H.S.; Kang, M.; Heo, R.; Bae, Y.M.; Han, E.; Yang, S.; Park, W.S. Inhibition of voltage-dependent K+ channels by iloperidone in coronary arterial smooth muscle cells. J. Appl. Toxicol. 2020, 40, 1297–1305. [Google Scholar] [CrossRef]
- Mazer-Amirshahi, M.; Porter, R.; Dewey, K. Prolonged QRS Widening After Aripiprazole Overdose. Pediatr. Emerg. Care 2018. Publish Ahead of Print. [Google Scholar] [CrossRef]
- Djamgoz, M.B.A.; Fraser, S.P.; Brackenbury, W.J. In Vivo Evidence for Voltage-Gated Sodium Channel Expression in Carcinomas and Potentiation of Metastasis. Cancers 2019, 11, 1675. [Google Scholar] [CrossRef]
- Dutta, S.; Lopez Charcas, O.; Tanner, S.; Gradek, F.; Driffort, V.; Roger, S.; Selander, K.; Velu, S.E.; Brouillette, W. Discovery and evaluation of nNav1.5 sodium channel blockers with potent cell invasion inhibitory activity in breast cancer cells. Bioorganic Med. Chem. 2018, 26, 2428–2436. [Google Scholar] [CrossRef]
- Föhr, K.J.; Nastos, A.; Fauler, M.; Zimmer, T.; Jungwirth, B.; Messerer, D.A.C. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front. Pharmacol. 2021, 12, 622489. [Google Scholar] [CrossRef]
- Fuchs, E.; Messerer, D.A.C.; Karpel-Massler, G.; Fauler, M.; Zimmer, T.; Jungwirth, B.; Föhr, K.J. Block of Voltage-Gated Sodium Channels as a Potential Novel Anti-cancer Mechanism of TIC10. Front. Pharmacol. 2021, 12, 737637. [Google Scholar] [CrossRef]
- Wang, G.K.; Wang, S.-Y. Block of Human Cardiac Sodium Channels by Lacosamide: Evidence for Slow Drug Binding along the Activation Pathway. Mol. Pharmacol. 2014, 85, 692–702. [Google Scholar] [CrossRef] [Green Version]
- Ragsdale, D.S.; McPhee, J.C.; Scheuer, T.; Catterall, W.A. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994, 265, 1724–1728. [Google Scholar] [CrossRef]
- Ragsdale, D.S.; McPhee, J.C.; Scheuer, T.; Catterall, W.A. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc. Natl. Acad. Sci. USA 1996, 93, 9270–9275. [Google Scholar] [CrossRef] [Green Version]
- Lawler, C.P.; Prioleau, C.; Lewis, M.M.; Mak, C.; Jiang, D.; Schetz, J.A.; Gonzalez, A.M.; Sibley, D.R.; Mailman, R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20, 612–627. [Google Scholar] [CrossRef]
- Pacher, P.; Kecskemeti, V. Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns? CPD 2004, 10, 2463–2475. [Google Scholar] [CrossRef] [Green Version]
- Li, K.J.; Greenstein, A.P.; Delisi, L.E. Sudden death in schizophrenia. Curr. Opin. Psychiatry 2018, 31, 169–175. [Google Scholar] [CrossRef]
- Ruiz Diaz, J.C.; Frenkel, D.; Aronow, W.S. The relationship between atypical antipsychotics drugs, QT interval prolongation, and torsades de pointes: Implications for clinical use. Expert Opin. Drug Saf. 2020, 19, 559–564. [Google Scholar] [CrossRef]
- Beach, S.R.; Celano, C.M.; Sugrue, A.M.; Adams, C.; Ackerman, M.J.; Noseworthy, P.A.; Huffman, J.C. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics 2018, 59, 105–122. [Google Scholar] [CrossRef] [PubMed]
- Yang, T.-T.; Wang, S.-J. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: Possible relevance to neuroprotective interventions in schizophrenia. Synapse 2008, 62, 804–818. [Google Scholar] [CrossRef]
- Sparshatt, A.; Taylor, D.; Patel, M.X.; Kapur, S. A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J. Clin. Psychiatry 2010, 71, 1447–1456. [Google Scholar] [CrossRef] [PubMed]
- Ilyin, V.I.; Hodges, D.D.; Whittemore, E.R.; Carter, R.B.; Cai, S.X.; Woodward, R.M. V102862 (Co 102862): A potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels. Br. J. Pharmacol. 2005, 144, 801–812. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Föhr, K.J.; Knippschild, U.; Herkommer, A.; Fauler, M.; Peifer, C.; Georgieff, M.; Adolph, O. State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261. Investig. New Drugs 2017, 35, 277–289. [Google Scholar] [CrossRef]
- Lenkey, N.; Karoly, R.; Lukacs, P.; Vizi, E.S.; Sunesen, M.; Fodor, L.; Mike, A. Classification of drugs based on properties of sodium channel inhibition: A comparative automated patch-clamp study. PLoS ONE 2010, 5, e15568. [Google Scholar] [CrossRef] [Green Version]
- Lei, M.; Wu, L.; Terrar, D.A.; Huang, C.L.-H. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation 2018, 138, 1879–1896. [Google Scholar] [CrossRef]
- Pless, S.A.; Galpin, J.D.; Frankel, A.; Ahern, C.A. Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels. Nat. Commun. 2011, 2, 351. [Google Scholar] [CrossRef] [Green Version]
- Nau, C.; Wang, S.Y.; Strichartz, G.R.; Wang, G.K. Block of human heart hH1 sodium channels by the enantiomers of bupivacaine. Anesthesiology 2000, 93, 1022–1033. [Google Scholar] [CrossRef]
- Stoetzer, C.; Voelker, M.; Doll, T.; Heineke, J.; Wegner, F.; Leffler, A. Cardiotoxic Antiemetics Metoclopramide and Domperidone Block Cardiac Voltage-Gated Na+ Channels. Anesth. Analg. 2017, 124, 52–60. [Google Scholar] [CrossRef]
- De Bellis, M.; Carbonara, R.; Roussel, J.; Farinato, A.; Massari, A.; Pierno, S.; Muraglia, M.; Corbo, F.; Franchini, C.; Carratù, M.R.; et al. Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity. Neuropharmacology 2017, 113, 206–216. [Google Scholar] [CrossRef] [Green Version]
- Delk, C.; Holstege, C.P.; Brady, W.J. Electrocardiographic abnormalities associated with poisoning. Am. J. Emerg. Med. 2007, 25, 672–687. [Google Scholar] [CrossRef]
- Cordes, J.; Li, C.; Dugas, J.; Austin-LaFrance, R.; Lightbown, I.; Engwall, M.; Sutton, M.; Steidl-Nichols, J. Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening. J. Pharmacol. Toxicol. Methods 2009, 60, 221. [Google Scholar] [CrossRef]
- Harmer, A.R.; Valentin, J.-P.; Pollard, C.E. On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex. Br. J. Pharmacol. 2011, 164, 260–273. [Google Scholar] [CrossRef] [Green Version]
- Belardinelli, L.; Liu, G.; Smith-Maxwell, C.; Wang, W.-Q.; El-Bizri, N.; Hirakawa, R.; Karpinski, S.; Li, C.H.; Hu, L.; Li, X.-J.; et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J. Pharmacol. Exp. Ther. 2013, 344, 23–32. [Google Scholar] [CrossRef]
- Matsuo, T.; Izumi, Y.; Kume, T.; Takada-Takatori, Y.; Sawada, H.; Akaike, A. Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures. Neurosci. Lett. 2010, 481, 78–81. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.Y.; Tae, I.H.; Lee, B.-M.; Kim, H.S.; Yoon, S. Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells. Anticancer Res. 2018, 38, 5101–5108. [Google Scholar] [CrossRef]
- Walzik, S.; Schroeter, A.; Benndorf, K.; Zimmer, T. Alternative Splicing of the Cardiac Sodium Channel Creates Multiple Variants of Mutant T1620K Channels. PLoS ONE 2011, 6, e19188. [Google Scholar] [CrossRef]
- Ludolph, A.G.; Udvardi, P.T.; Schaz, U.; Henes, C.; Adolph, O.; Weigt, H.U.; Fegert, J.M.; Boeckers, T.M.; Föhr, K.J. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br. J. Pharmacol. 2010, 160, 283–291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamill, O.P.; Marty, A.; Neher, E.; Sakmann, B.; Sigworth, F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981, 391, 85–100. [Google Scholar] [CrossRef]
- Desaphy, J.F.; De Luca, A.; Camerino, D.C. Blockade by cAMP of native sodium channels of adult rat skeletal muscle fibers. Am. J. Physiol. 1998, 275, C1465–C1472. [Google Scholar] [CrossRef] [PubMed]
- Bean, B.P.; Cohen, C.J.; Tsien, R.W. Lidocaine block of cardiac sodium channels. J. Gen. Physiol. 1983, 81, 613–642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuo, C.C.; Lu, L. Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br. J. Pharmacol. 1997, 121, 1231–1238. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Föhr, K.J.; Rapp, M.; Fauler, M.; Zimmer, T.; Jungwirth, B.; Messerer, D.A.C. Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner. Int. J. Mol. Sci. 2022, 23, 12890. https://doi.org/10.3390/ijms232112890
Föhr KJ, Rapp M, Fauler M, Zimmer T, Jungwirth B, Messerer DAC. Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner. International Journal of Molecular Sciences. 2022; 23(21):12890. https://doi.org/10.3390/ijms232112890
Chicago/Turabian StyleFöhr, Karl Josef, Michael Rapp, Michael Fauler, Thomas Zimmer, Bettina Jungwirth, and David Alexander Christian Messerer. 2022. "Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner" International Journal of Molecular Sciences 23, no. 21: 12890. https://doi.org/10.3390/ijms232112890